Shi‐Man Zhang

699 total citations
21 papers, 492 citations indexed

About

Shi‐Man Zhang is a scholar working on Biomedical Engineering, Immunology and Biotechnology. According to data from OpenAlex, Shi‐Man Zhang has authored 21 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Biomedical Engineering, 11 papers in Immunology and 5 papers in Biotechnology. Recurrent topics in Shi‐Man Zhang's work include Nanoplatforms for cancer theranostics (13 papers), Immune cells in cancer (7 papers) and interferon and immune responses (5 papers). Shi‐Man Zhang is often cited by papers focused on Nanoplatforms for cancer theranostics (13 papers), Immune cells in cancer (7 papers) and interferon and immune responses (5 papers). Shi‐Man Zhang collaborates with scholars based in China and Iran. Shi‐Man Zhang's co-authors include Xian‐Zheng Zhang, Xiao‐Kang Jin, Jun‐Long Liang, Qian‐Xiao Huang, Wei‐Hai Chen, Chuan‐Jun Liu, Si‐Xue Cheng, Ping Ji, Ping Ji and Guo‐Feng Luo and has published in prestigious journals such as Journal of the American Chemical Society, Advanced Materials and Nano Letters.

In The Last Decade

Shi‐Man Zhang

21 papers receiving 483 citations

Peers

Shi‐Man Zhang
Dailin Xu China
Duo Gao China
Jingbo Ma China
Kun Shang China
Shi‐Man Zhang
Citations per year, relative to Shi‐Man Zhang Shi‐Man Zhang (= 1×) peers Xuemeng Guo

Countries citing papers authored by Shi‐Man Zhang

Since Specialization
Citations

This map shows the geographic impact of Shi‐Man Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Man Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Man Zhang more than expected).

Fields of papers citing papers by Shi‐Man Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐Man Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Man Zhang. The network helps show where Shi‐Man Zhang may publish in the future.

Co-authorship network of co-authors of Shi‐Man Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐Man Zhang. A scholar is included among the top collaborators of Shi‐Man Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐Man Zhang. Shi‐Man Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xiaoyang, Cheng Zhang, Yun Zhang, et al.. (2025). Biomineralized Engineered Bacterial Outer Membrane Vesicles as cGAS-STING Nanoagonists Synergize with Lactate Metabolism Modulation to Potentiate Immunotherapy. Journal of the American Chemical Society. 147(28). 24555–24572. 13 indexed citations
4.
Chen, Wei‐Hai, Ziyi Han, Shi‐Man Zhang, et al.. (2025). Targeted tumor therapy with L-cyst(e)ine-addicted bacteria-nanodrug biohybrids. Cell Metabolism. 37(6). 1277–1293.e8. 5 indexed citations
5.
Jin, Xiao‐Kang, et al.. (2025). An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer. Nature Nanotechnology. 20(7). 935–946. 10 indexed citations
6.
Meng, Ran, Shi‐Man Zhang, Hong Chen, et al.. (2025). Acid-Responsive Biocompatible Hydrogel Modulating Tumor DNA Self-Repair Collaborated with Chemotherapy for Boosting STING Pathway-Associated Immunotherapy. Nano Letters. 25(9). 3670–3680. 2 indexed citations
7.
Pan, Ting, Yuliang Sun, Shi‐Man Zhang, et al.. (2025). Biomimetic artificial enveloped viral vectors: Overcoming immune barriers for re-administration and long-term gene therapy. 1(7). 100143–100143. 2 indexed citations
8.
Liang, Jun‐Long, Xiao‐Kang Jin, Qian‐Xiao Huang, et al.. (2024). Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy. Materials Today. 78. 251–296. 14 indexed citations
9.
Kuang, Jing, Ting Pan, Qian‐Xiao Huang, et al.. (2024). Cationic Magnetic Nanoparticles Activate Natural Killer Cells for the Treatment of Glioblastoma. ACS Nano. 19(1). 649–661. 7 indexed citations
10.
Liang, Jun‐Long, Shi‐Man Zhang, Ran Meng, et al.. (2024). Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy. Advanced Materials. 36(36). e2405673–e2405673. 25 indexed citations
11.
Ji, Ping, Xiao‐Kang Jin, Shi‐Man Zhang, et al.. (2024). Metabolic Regulation-Mediated Reversion of the Tumor Immunosuppressive Microenvironment for Potentiating Cooperative Metabolic Therapy and Immunotherapy. Nano Letters. 24(15). 4691–4701. 6 indexed citations
12.
Jin, Xiao‐Kang, Shi‐Man Zhang, Jun‐Long Liang, et al.. (2024). Disrupting Intracellular Homeostasis by Copper‐Based Nanoinducer with Multiple Enzyme‐Mimicking Activities to Induce Disulfidptosis‐Enhanced Pyroptosis for Tumor Immunotherapy. Advanced Materials. 37(1). e2410957–e2410957. 34 indexed citations
13.
Liang, Jun‐Long, Xiao‐Kang Jin, Shi‐Man Zhang, et al.. (2023). Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Science Bulletin. 68(6). 622–636. 96 indexed citations
14.
Liang, Jun‐Long, Xiao‐Kang Jin, Guo‐Feng Luo, et al.. (2023). Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy. ACS Nano. 17(17). 17217–17232. 47 indexed citations
15.
Zhang, Shi‐Man, Xiao‐Kang Jin, Guo‐Feng Luo, et al.. (2023). An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity. ACS Materials Letters. 5(10). 2785–2798. 14 indexed citations
16.
Jin, Xiao‐Kang, Jun‐Long Liang, Shi‐Man Zhang, et al.. (2023). Engineering metal-based hydrogel-mediated tertiary lymphoid structure formation via activation of the STING pathway for enhanced immunotherapy. Materials Horizons. 10(10). 4365–4379. 40 indexed citations
17.
Jin, Xiao‐Kang, Shi‐Man Zhang, Jun‐Long Liang, et al.. (2023). A PD‐L1‐targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition‐Mediated Synergistic Antitumor Metabolic and Immune Therapy. Advanced Materials. 36(6). e2309094–e2309094. 24 indexed citations
18.
Ji, Ping, Xiao‐Kang Jin, Shi‐Man Zhang, et al.. (2023). Fused Cytomembrane‐Camouflaged Nanoparticles for Tumor‐Specific Immunotherapy. Advanced Healthcare Materials. 12(23). e2300323–e2300323. 16 indexed citations
19.
Jin, Xiao‐Kang, Jun‐Long Liang, Shi‐Man Zhang, et al.. (2023). Orchestrated copper-based nanoreactor for remodeling tumor microenvironment to amplify cuproptosis-mediated anti-tumor immunity in colorectal cancer. Materials Today. 68. 108–124. 108 indexed citations
20.
Liang, Jun‐Long, Mei‐Ting Niu, Guo‐Feng Luo, et al.. (2022). Tailor-made biotuner against colorectal tumor microenvironment to transfer harms into treasures for synergistic oncotherapy. Nano Today. 47. 101662–101662. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026